
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News / Product</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Mon, 22 Feb 2010 00:55:37 EET</pubDate>
<language>en</language>
<item>
<title><![CDATA[Randox Therapeutic Drug Monitoring (TDM) kits and quality controls]]></title>
<link>http://www.worldpharmanews.net/Product/Randox_Therapeutic_Drug_Monitoring_TDM_kits_and_quality_controls/</link>
<comments>http://www.worldpharmanews.net/Product/Randox_Therapeutic_Drug_Monitoring_TDM_kits_and_quality_controls/</comments>
<pubDate>Mon, 22 Feb 2010 00:55:37 EET</pubDate>
<dc:creator>Randox</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Randox_Therapeutic_Drug_Monitoring_TDM_kits_and_quality_controls/</guid>
<description><![CDATA[Randox Therapeutic Drug Monitoring (TDM) kits offer accurate determination of drugs in a patient's blood, ensuring they receive the most effective dosage of medication with the least possible toxicit<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Reliable HbA1c testing now available on the RX Monza | PressReleasePoint]]></title>
<link>http://www.worldpharmanews.net/Product/Reliable_HbA1c_testing_now_available_on_the_RX_Monza__PressReleasePoint/</link>
<comments>http://www.worldpharmanews.net/Product/Reliable_HbA1c_testing_now_available_on_the_RX_Monza__PressReleasePoint/</comments>
<pubDate>Fri, 12 Feb 2010 01:31:24 EET</pubDate>
<dc:creator>Randox</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Reliable_HbA1c_testing_now_available_on_the_RX_Monza__PressReleasePoint/</guid>
<description><![CDATA[The RX monza is a compact, semi-automated, clinical chemistry analyser for routine and specialised diagnostic testing with an ever expanding test menu, now including HbA1c.The RX monza is a compact<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[NEW Liquid quality control sera available now!]]></title>
<link>http://www.worldpharmanews.net/Product/NEW_Liquid_quality_control_sera_available_now/</link>
<comments>http://www.worldpharmanews.net/Product/NEW_Liquid_quality_control_sera_available_now/</comments>
<pubDate>Thu, 11 Feb 2010 22:44:40 EET</pubDate>
<dc:creator>Randox</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/NEW_Liquid_quality_control_sera_available_now/</guid>
<description><![CDATA[The Randox Acusera range of quality control sera is set to expand with the introduction of our new liquid ready to use QC.  Liquid controls eliminate the need for reconstitution minimising the risk o<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Three new Novartis medicines approved in Japan]]></title>
<link>http://www.worldpharmanews.net/Product/Three_new_Novartis_medicines_approved_in_Japan/</link>
<comments>http://www.worldpharmanews.net/Product/Three_new_Novartis_medicines_approved_in_Japan/</comments>
<pubDate>Tue, 26 Jan 2010 00:42:24 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Three_new_Novartis_medicines_approved_in_Japan/</guid>
<description><![CDATA[Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (val<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_approves_ACTEMRA_for_the_treatment_of_moderately_to_severely_active_rheumatoid_arthritis/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_approves_ACTEMRA_for_the_treatment_of_moderately_to_severely_active_rheumatoid_arthritis/</comments>
<pubDate>Fri, 15 Jan 2010 00:42:02 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_approves_ACTEMRA_for_the_treatment_of_moderately_to_severely_active_rheumatoid_arthritis/</guid>
<description><![CDATA[Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult <br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Rapid drugs of abuse screening from Randox]]></title>
<link>http://www.worldpharmanews.net/Product/Rapid_drugs_of_abuse_screening_from_Randox/</link>
<comments>http://www.worldpharmanews.net/Product/Rapid_drugs_of_abuse_screening_from_Randox/</comments>
<pubDate>Tue, 24 Nov 2009 23:19:02 EET</pubDate>
<dc:creator>Randox</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Rapid_drugs_of_abuse_screening_from_Randox/</guid>
<description><![CDATA[Randox have developed an innovative multi-marker drugs of abuse testing procedure for rapid drug screening programmes. The Drugs of Abuse(DoA) biochips permit the analysis of up to 10 drug classes fr<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Advisory Committee Finds Data Support SPIRIVA HandiHaler]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Advisory_Committee_Finds_Data_Support_SPIRIVA%AE_HandiHaler%AE/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Advisory_Committee_Finds_Data_Support_SPIRIVA%AE_HandiHaler%AE/</comments>
<pubDate>Mon, 23 Nov 2009 15:09:44 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Advisory_Committee_Finds_Data_Support_SPIRIVA%AE_HandiHaler%AE/</guid>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor)]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_US_New_Drug_Application_for_Brilinta_Ticagrelor/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_US_New_Drug_Application_for_Brilinta_Ticagrelor/</comments>
<pubDate>Mon, 23 Nov 2009 15:09:23 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_US_New_Drug_Application_for_Brilinta_Ticagrelor/</guid>
<description><![CDATA[AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Randox unveils cardiac care technology at major European medical event]]></title>
<link>http://www.worldpharmanews.net/Product/Randox_unveils_cardiac_care_technology_at_major_European_medical_event/</link>
<comments>http://www.worldpharmanews.net/Product/Randox_unveils_cardiac_care_technology_at_major_European_medical_event/</comments>
<pubDate>Fri, 20 Nov 2009 21:43:03 EET</pubDate>
<dc:creator>Randox</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Randox_unveils_cardiac_care_technology_at_major_European_medical_event/</guid>
<description><![CDATA[RANDOX Laboratories (&quot;Randox&quot;), the Antrim-based independent global diagnostics company, will today unveil a revolutionary new cardiac machine at the world's largest medical trade fair being held thi<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Prometheus Launches ProOncDx Cancer Diagnostics]]></title>
<link>http://www.worldpharmanews.net/Product/Prometheus_Launches_ProOncDx_Cancer_Diagnostics-1/</link>
<comments>http://www.worldpharmanews.net/Product/Prometheus_Launches_ProOncDx_Cancer_Diagnostics-1/</comments>
<pubDate>Wed, 18 Nov 2009 02:22:42 EET</pubDate>
<dc:creator>PharmaNews1</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Prometheus_Launches_ProOncDx_Cancer_Diagnostics-1/</guid>
<description><![CDATA[Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company launched three new cancer diagnostic products: ProOnc TumorSourceDx, ProOnc SquamousDx and ProOnc MesotheliomaDx. Each <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA approves GSK's pandemic H1N1 vaccine]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_approves_GSKs_pandemic_H1N1_vaccine/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_approves_GSKs_pandemic_H1N1_vaccine/</comments>
<pubDate>Fri, 13 Nov 2009 02:13:07 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_approves_GSKs_pandemic_H1N1_vaccine/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccin<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The risk of venous thromboembolism (VTE) associated with oral hormonal contraceptives]]></title>
<link>http://www.worldpharmanews.net/Product/The_risk_of_venous_thromboembolism_VTE_associated_with_oral_hormonal_contraceptives/</link>
<comments>http://www.worldpharmanews.net/Product/The_risk_of_venous_thromboembolism_VTE_associated_with_oral_hormonal_contraceptives/</comments>
<pubDate>Wed, 28 Oct 2009 01:12:51 EET</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/The_risk_of_venous_thromboembolism_VTE_associated_with_oral_hormonal_contraceptives/</guid>
<description><![CDATA[The Swiss regulatory authority Swissmedic has conducted an analysis with its expert medical committee on the latest data and studies regarding the risk of venous thromboembolism (VTE) associated with<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine]]></title>
<link>http://www.worldpharmanews.net/Product/U-S-_FDA_Licenses_Sanofi_Pasteurs_Pandemic_Influenza_Vaccine-1/</link>
<comments>http://www.worldpharmanews.net/Product/U-S-_FDA_Licenses_Sanofi_Pasteurs_Pandemic_Influenza_Vaccine-1/</comments>
<pubDate>Mon, 21 Sep 2009 01:22:11 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/U-S-_FDA_Licenses_Sanofi_Pasteurs_Pandemic_Influenza_Vaccine-1/</guid>
<description><![CDATA[Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental bi<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[CJC 1295, Mechano Growth Factor]]></title>
<link>http://www.worldpharmanews.net/Product/CJC_1295_Mechano_Growth_Factor/</link>
<comments>http://www.worldpharmanews.net/Product/CJC_1295_Mechano_Growth_Factor/</comments>
<pubDate>Sun, 23 Aug 2009 00:15:45 EEST</pubDate>
<dc:creator>purepeptides</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/CJC_1295_Mechano_Growth_Factor/</guid>
<description><![CDATA[Purepeptides, LLC is a leader in the production of protein peptides. Purepeptides provides the highest quality research protein peptides, and growth releasing factors, for the lowest prices available<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves ONGLYZA for the Treatment of Type 2 Diabetes in the US]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_ONGLYZA_for_the_Treatment_of_Type_2_Diabetes_in_the_US/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_ONGLYZA_for_the_Treatment_of_Type_2_Diabetes_in_the_US/</comments>
<pubDate>Tue, 04 Aug 2009 10:51:34 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_ONGLYZA_for_the_Treatment_of_Type_2_Diabetes_in_the_US/</guid>
<description><![CDATA[AstraZeneca and Bristol-Myers Squibb today announced that the US Food and Drug Administration (FDA) has approved ONGLYZA (saxagliptin) for the treatment of type 2 diabetes mellitus in adults. ONGLYZA<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US]]></title>
<link>http://www.worldpharmanews.net/Product/Bayer_submits_first-in-class_estradiol-based_oral_contraceptive_for_approval_in_the_US/</link>
<comments>http://www.worldpharmanews.net/Product/Bayer_submits_first-in-class_estradiol-based_oral_contraceptive_for_approval_in_the_US/</comments>
<pubDate>Fri, 10 Jul 2009 10:10:48 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Bayer_submits_first-in-class_estradiol-based_oral_contraceptive_for_approval_in_the_US/</guid>
<description><![CDATA[Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new estradiol-based oral contraceptive (estradiol valerate/dienogest). It seeks approval for the <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Commission approves statement on lipid improvement for Viramune label]]></title>
<link>http://www.worldpharmanews.net/Product/European_Commission_approves_statement_on_lipid_improvement_for_Viramune%AE_label/</link>
<comments>http://www.worldpharmanews.net/Product/European_Commission_approves_statement_on_lipid_improvement_for_Viramune%AE_label/</comments>
<pubDate>Thu, 09 Jul 2009 00:12:10 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Commission_approves_statement_on_lipid_improvement_for_Viramune%AE_label/</guid>
<description><![CDATA[Boehringer Ingelheim announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for Viramune® (nevirapine) in the treatment of patients with HIV. T<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Takes Actions on Darvon, Other Pain Medications Containing Propoxyphene]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Takes_Actions_on_Darvon_Other_Pain_Medications_Containing_Propoxyphene/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Takes_Actions_on_Darvon_Other_Pain_Medications_Containing_Propoxyphene/</comments>
<pubDate>Thu, 09 Jul 2009 00:04:59 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Takes_Actions_on_Darvon_Other_Pain_Medications_Containing_Propoxyphene/</guid>
<description><![CDATA[The U.S. Food and Drug Administration is taking several actions to reduce the risk of overdose in patients using pain medications such as Darvon and Darvocet that contain propoxyphene. The actions we<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes]]></title>
<link>http://www.worldpharmanews.net/Product/ONGLYZA_saxagliptin_Receives_Positive_Opinion_in_Europe_for_the_Treatment_of_Type_2_Diabetes/</link>
<comments>http://www.worldpharmanews.net/Product/ONGLYZA_saxagliptin_Receives_Positive_Opinion_in_Europe_for_the_Treatment_of_Type_2_Diabetes/</comments>
<pubDate>Tue, 30 Jun 2009 21:46:09 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/ONGLYZA_saxagliptin_Receives_Positive_Opinion_in_Europe_for_the_Treatment_of_Type_2_Diabetes/</guid>
<description><![CDATA[AstraZeneca and Bristol-Myers Squibb Company today announced that their marketing authorisation application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Prod<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lundbeck receives FDA Complete Response Letter on Serdolect for the treatment of schizophrenia]]></title>
<link>http://www.worldpharmanews.net/Product/Lundbeck_receives_FDA_Complete_Response_Letter_on_Serdolect%AE_for_the_treatment_of_schizophrenia/</link>
<comments>http://www.worldpharmanews.net/Product/Lundbeck_receives_FDA_Complete_Response_Letter_on_Serdolect%AE_for_the_treatment_of_schizophrenia/</comments>
<pubDate>Sun, 28 Jun 2009 01:14:18 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Lundbeck_receives_FDA_Complete_Response_Letter_on_Serdolect%AE_for_the_treatment_of_schizophrenia/</guid>
<description><![CDATA[H. Lundbeck A/S (LUN.CO; LUN DC) has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Serdolect® (sertindole) for the treatment of schizophrenia.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission]]></title>
<link>http://www.worldpharmanews.net/Product/Nycomed_receives_Marketing_Authorization_for_Pantoprazole_20mg_OTC_from_European_Commission/</link>
<comments>http://www.worldpharmanews.net/Product/Nycomed_receives_Marketing_Authorization_for_Pantoprazole_20mg_OTC_from_European_Commission/</comments>
<pubDate>Tue, 23 Jun 2009 00:09:57 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Nycomed_receives_Marketing_Authorization_for_Pantoprazole_20mg_OTC_from_European_Commission/</guid>
<description><![CDATA[Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®. This new O<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease]]></title>
<link>http://www.worldpharmanews.net/Product/Genzyme_Receives_European_Approval_of_Renvela_for_Patients_with_Chronic_Kidney_Disease/</link>
<comments>http://www.worldpharmanews.net/Product/Genzyme_Receives_European_Approval_of_Renvela_for_Patients_with_Chronic_Kidney_Disease/</comments>
<pubDate>Wed, 17 Jun 2009 02:47:16 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Genzyme_Receives_European_Approval_of_Renvela_for_Patients_with_Chronic_Kidney_Disease/</guid>
<description><![CDATA[Genzyme Corporation (Nasdaq: GENZ) announced that the European Commission has approved Renvela® (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease (CKD)<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe]]></title>
<link>http://www.worldpharmanews.net/Product/Takeda_to_Revise_Timing_of_Alogliptin_and_AlogliptinACTOS_MAA_Filing_in_Europe/</link>
<comments>http://www.worldpharmanews.net/Product/Takeda_to_Revise_Timing_of_Alogliptin_and_AlogliptinACTOS_MAA_Filing_in_Europe/</comments>
<pubDate>Mon, 15 Jun 2009 00:03:23 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Takeda_to_Revise_Timing_of_Alogliptin_and_AlogliptinACTOS_MAA_Filing_in_Europe/</guid>
<description><![CDATA[Takeda Pharmaceutical Company Limited (&quot;Takeda&quot;) has reviewed the development strategy for the Marketing Authorization Applications (MAAs) for its investigational compounds, alogliptin and aloglipt<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure]]></title>
<link>http://www.worldpharmanews.net/Product/New_Study_Shows_NplateR_Significantly_Reduces_Splenectomy_Rate_and_Treatment_Failure/</link>
<comments>http://www.worldpharmanews.net/Product/New_Study_Shows_NplateR_Significantly_Reduces_Splenectomy_Rate_and_Treatment_Failure/</comments>
<pubDate>Tue, 09 Jun 2009 00:26:23 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/New_Study_Shows_NplateR_Significantly_Reduces_Splenectomy_Rate_and_Treatment_Failure/</guid>
<description><![CDATA[Amgen Inc. (Nasdaq: AMGN) released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thromboc<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Receives Positive Opinion for European Approval of Mozobil]]></title>
<link>http://www.worldpharmanews.net/Product/Genzyme_Receives_Positive_Opinion_for_European_Approval_of_Mozobil/</link>
<comments>http://www.worldpharmanews.net/Product/Genzyme_Receives_Positive_Opinion_for_European_Approval_of_Mozobil/</comments>
<pubDate>Mon, 01 Jun 2009 20:33:36 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Genzyme_Receives_Positive_Opinion_for_European_Approval_of_Mozobil/</guid>
<description><![CDATA[Genzyme Corp. (Nasdaq: GENZ) announced that the European Medicines Agency's Committee for Human Medicinal Products (CHMP) has adopted a positive opinion on the marketing authorization application fo<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_Regulatory_Update_on_Seroquel_XR_for_the_Treatment_of_Major_Depressive_Disorder/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_Regulatory_Update_on_Seroquel_XR_for_the_Treatment_of_Major_Depressive_Disorder/</comments>
<pubDate>Sat, 30 May 2009 23:17:21 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_Regulatory_Update_on_Seroquel_XR_for_the_Treatment_of_Major_Depressive_Disorder/</guid>
<description><![CDATA[AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult pa<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New data to be presented on Abbott's market-leading XIENCE V(R) stent]]></title>
<link>http://www.worldpharmanews.net/Product/New_data_to_be_presented_on_Abbotts_market-leading_XIENCE_VR_stent/</link>
<comments>http://www.worldpharmanews.net/Product/New_data_to_be_presented_on_Abbotts_market-leading_XIENCE_VR_stent/</comments>
<pubDate>Thu, 21 May 2009 00:54:39 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/New_data_to_be_presented_on_Abbotts_market-leading_XIENCE_VR_stent/</guid>
<description><![CDATA[Abbott (NYSE: ABT) has announced the company's schedule of major events and news announcements during EuroPCR 2009 in Barcelona, May 19 - 22. These include the presentation of new data from the SPIR<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis receives approval from FDA to market Prevacid]]></title>
<link>http://www.worldpharmanews.net/Product/Novartis_receives_approval_from_FDA_to_market_Prevacid%AE/</link>
<comments>http://www.worldpharmanews.net/Product/Novartis_receives_approval_from_FDA_to_market_Prevacid%AE/</comments>
<pubDate>Mon, 18 May 2009 00:50:28 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Novartis_receives_approval_from_FDA_to_market_Prevacid%AE/</guid>
<description><![CDATA[Novartis announced today that Prevacid® 24HR (lansoprazole delayed-release capsules 15 mg) has been approved by the US Food and Drug Administration (FDA) as the first over-the-counter (OTC) Proton Pu<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed files European marketing authorisation application for Daxas]]></title>
<link>http://www.worldpharmanews.net/Product/Nycomed_files_European_marketing_authorisation_application_for_Daxas%AE/</link>
<comments>http://www.worldpharmanews.net/Product/Nycomed_files_European_marketing_authorisation_application_for_Daxas%AE/</comments>
<pubDate>Mon, 11 May 2009 19:41:37 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Nycomed_files_European_marketing_authorisation_application_for_Daxas%AE/</guid>
<description><![CDATA[Nycomed has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Daxas® as a once-daily oral treatment for patients with COPD associated<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Medicines Agency recommendations on extension of shelf life for Tamiflu]]></title>
<link>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommendations_on_extension_of_shelf_life_for_Tamiflu/</link>
<comments>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommendations_on_extension_of_shelf_life_for_Tamiflu/</comments>
<pubDate>Sun, 10 May 2009 00:36:23 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommendations_on_extension_of_shelf_life_for_Tamiflu/</guid>
<description><![CDATA[The European Medicines Agency has recommended that the shelf life of Tamiflu capsules should be extended from five to seven years. Once formally approved by the European Commission, this will apply t<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene]]></title>
<link>http://www.worldpharmanews.net/Product/Lilly_Granted_Preliminary_Injunction_to_Prevent_Launch_of_Generic_Raloxifene/</link>
<comments>http://www.worldpharmanews.net/Product/Lilly_Granted_Preliminary_Injunction_to_Prevent_Launch_of_Generic_Raloxifene/</comments>
<pubDate>Tue, 28 Apr 2009 00:40:21 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Lilly_Granted_Preliminary_Injunction_to_Prevent_Launch_of_Generic_Raloxifene/</guid>
<description><![CDATA[Eli Lilly and Company (NYSE: LLY) announced that the U.S. District Court for the Southern District of Indiana has issued a preliminary injunction to prevent the launch of a generic version of Lilly'<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK submits Tyverb/Tykerb for first-line treatment of metastatic breast cancer in Europe, US]]></title>
<link>http://www.worldpharmanews.net/Product/GSK_submits_Tyverb%AETykerb%AE_for_first-line_treatment_of_metastatic_breast_cancer_in_Europe_US/</link>
<comments>http://www.worldpharmanews.net/Product/GSK_submits_Tyverb%AETykerb%AE_for_first-line_treatment_of_metastatic_breast_cancer_in_Europe_US/</comments>
<pubDate>Fri, 03 Apr 2009 00:05:30 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GSK_submits_Tyverb%AETykerb%AE_for_first-line_treatment_of_metastatic_breast_cancer_in_Europe_US/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) has announced the submission of two simultaneous regulatory applications to expand the use of Tyverb®/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Caraco Digoxin Recall Issued March 31, 2009 Is Due To Pill-Size Problems]]></title>
<link>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Caraco_Digoxin_Recall_Issued_March_31_2009_Is_Due_To_Pill-Size_Problems/</link>
<comments>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Caraco_Digoxin_Recall_Issued_March_31_2009_Is_Due_To_Pill-Size_Problems/</comments>
<pubDate>Wed, 01 Apr 2009 02:19:20 EEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Caraco_Digoxin_Recall_Issued_March_31_2009_Is_Due_To_Pill-Size_Problems/</guid>
<description><![CDATA[Digitek Brand Of Generic Digoxin Tablets Had Been Recalled In April 2008 For Same Reason<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[EMERFLU, pandemic influenza vaccine for humans, approved in Australia]]></title>
<link>http://www.worldpharmanews.net/Product/EMERFLU%AE_pandemic_influenza_vaccine_for_humans_approved_in_Australia/</link>
<comments>http://www.worldpharmanews.net/Product/EMERFLU%AE_pandemic_influenza_vaccine_for_humans_approved_in_Australia/</comments>
<pubDate>Mon, 30 Mar 2009 00:29:43 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/EMERFLU%AE_pandemic_influenza_vaccine_for_humans_approved_in_Australia/</guid>
<description><![CDATA[Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its pandemic influenza vaccine for human use Emerflu®, has been granted marketing authoriza<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[U.S. Patent &amp; Trademark Office Grants Reissue Patent Relating to Lipitor]]></title>
<link>http://www.worldpharmanews.net/Product/U-S-_Patent__Trademark_Office_Grants_Reissue_Patent_Relating_to_Lipitor/</link>
<comments>http://www.worldpharmanews.net/Product/U-S-_Patent__Trademark_Office_Grants_Reissue_Patent_Relating_to_Lipitor/</comments>
<pubDate>Sun, 22 Mar 2009 00:20:12 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/U-S-_Patent__Trademark_Office_Grants_Reissue_Patent_Relating_to_Lipitor/</guid>
<description><![CDATA[Pfizer Inc announced that the U.S. Patent &amp; Trademark Office has granted reissue patent RE40667, relating to Lipitor. The company had applied for the reissue patent in January 2007, in order to corre<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Warnings About Byetta Associated With Risk Of Severe Pancreatitis And Renal Failure]]></title>
<link>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Warnings_About_Byetta_Associated_With_Risk_Of_Severe_Pancreatitis_And_Renal_Failure/</link>
<comments>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Warnings_About_Byetta_Associated_With_Risk_Of_Severe_Pancreatitis_And_Renal_Failure/</comments>
<pubDate>Fri, 06 Mar 2009 00:05:15 EET</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Drug_Injury_Watch_Warnings_About_Byetta_Associated_With_Risk_Of_Severe_Pancreatitis_And_Renal_Failure/</guid>
<description><![CDATA[March 2009 Drug Safety Update Newsletter (UK) Raises Emerging Safety Issue Of Kidney-Related Side Effects From Byetta Use<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The safety of patients is of utmost importance to Merck]]></title>
<link>http://www.worldpharmanews.net/Product/The_safety_of_patients_is_of_utmost_importance_to_Merck/</link>
<comments>http://www.worldpharmanews.net/Product/The_safety_of_patients_is_of_utmost_importance_to_Merck/</comments>
<pubDate>Mon, 23 Feb 2009 00:07:26 EET</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/The_safety_of_patients_is_of_utmost_importance_to_Merck/</guid>
<description><![CDATA[Merck KGaA announced that the European Medicines Agency (EMEA) has recommended to the European Commission the suspension of the marketing authorization for Raptiva® (efalizumab). Raptiva is currently<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Accepts_Amgens_Submission_and_Files_Biologics_License_Application_for_Denosumab/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Accepts_Amgens_Submission_and_Files_Biologics_License_Application_for_Denosumab/</comments>
<pubDate>Fri, 20 Feb 2009 00:01:17 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Accepts_Amgens_Submission_and_Files_Biologics_License_Application_for_Denosumab/</guid>
<description><![CDATA[Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee]]></title>
<link>http://www.worldpharmanews.net/Product/Prasugrel_Receives_Unanimous_Approval_Recommendation_from_FDA_Advisory_Committee/</link>
<comments>http://www.worldpharmanews.net/Product/Prasugrel_Receives_Unanimous_Approval_Recommendation_from_FDA_Advisory_Committee/</comments>
<pubDate>Thu, 12 Feb 2009 00:17:55 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Prasugrel_Receives_Unanimous_Approval_Recommendation_from_FDA_Advisory_Committee/</guid>
<description><![CDATA[The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that prasugrel, an investigational antiplatelet agent, should be approved for the treatment of pat<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim)]]></title>
<link>http://www.worldpharmanews.net/Product/European_Commission_EC_has_granted_marketing_authorisation_for_NplateR_romiplostim/</link>
<comments>http://www.worldpharmanews.net/Product/European_Commission_EC_has_granted_marketing_authorisation_for_NplateR_romiplostim/</comments>
<pubDate>Mon, 09 Feb 2009 00:06:03 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Commission_EC_has_granted_marketing_authorisation_for_NplateR_romiplostim/</guid>
<description><![CDATA[Amgen (Nasdaq: AMGN) announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) <br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
